Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces a collaboration with BioGX, Inc.
(“
BioGX”), a global provider of easy molecular
diagnostic solutions. The companies are collaborating to make
Microbix’s Quality Assessment Products (“
QAPs™”)
available to BioGX Xfree
™ customers that perform
tests on the portable BioGX pixl
™ real-time PCR
platform, and other systems such as the Applied Biosystems
Quantstudio
™ 5 and 7500 Fast Dx, the BD MAX™, and
the Bio-Rad CFX96 Touch
™ and CFX384
Touch
™.
Microbix was chosen by BioGX to be the primary
External Quality Controls provider for assays on their
newly-launched pixl platform – a benchtop instrument with
capabilities for syndromic testing. To date, BioGX recommends nine
PROCEEDx™FLOQ® QAPs to be used in conjunction with
assays that detect a wide variety of infectious organisms,
including but not limited to SARS-CoV-2 (COVID), Influenza A&B
(Flu), Group A Streptococcus (Strep), Herpes Simplex Virus 1&2
(Herpes), Varicella Zoster Virus (Chicken Pox), Treponema pallidum
(Syphilis), and Mpox virus (Monkeypox).
Microbix QAPs are now referenced in BioGX Assay
Product Inserts (available at https://www.biogx.com), with
additional QAPs to be referenced as the collaboration expands.
Microbix’s current QAPs catalogue is available on its website at
https://microbix.com/request-catalogue/.
Xfree technology provides a complete lyophilized
test in a single tube – using the trusted BioGX Sample-Ready™
format for extraction-free, direct sample addition in real-time PCR
testing. This format eliminates pre-treatment and nucleic-acid
extraction steps, enabling labs with a simple Sample-to-Answer
workflow. The tests can be shipped anywhere in the world without
refrigeration, as can the QAPs.
Phil Casselli, SVP of Sales & Business
Development at Microbix, commented, “It has been a pleasure to work
with Robert and his team at BioGX to support their customer base
with robust External Quality Controls. They selected our unique
FLOQSwab® based QAPs because they replicate a patient specimen
closely, are extremely convenient to ship, store, and use, and
allow end-users to monitor their entire diagnostic workflow from
sample collection to result.”
Robert Martinez, VP of Business Development
& Scientific Affairs at BioGX, also commented, “We considered
other external quality controls, but selected Microbix QAPs as the
best solution to support assay optimization and to significantly
simplify QC procedures with minimal to no pipetting steps.
Microbix’s technical expertise, product design, performance, and
superior customer service are impressive. We look forward to
continuing our collaboration.”
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and annualized sales targeting C$ 2.0 million per month.
It makes a wide range of critical ingredients and devices for the
global diagnostics industry, notably antigens for immunoassays and
its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Its antigens drive the antibody tests of approximately
100 diagnostics makers, while QAPs are sold to clinical lab
accreditation organizations, diagnostics companies, and clinical
labs. Microbix QAPs are now available in over 30 countries,
supported by a network of 10 international distributors. Microbix
is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian
TGA registered, Health Canada establishment licensed, and provides
CE marked products.
About BioGX, Inc.BioGX is a
leading global provider of lyophilized real-time PCR reagents for
molecular diagnostics. BioGX, Inc., headquartered in Birmingham,
Alabama and Dallas, TX, and its wholly owned subsidiary BioGX B.V.,
based in Amsterdam, The Netherlands, (collectively “BioGX”),
operates in a cGMP compliant environment certified to ISO 13485
medical device development and manufacturing standards. The
proprietary Sample-Ready™ technology is at the core of all product
offerings for Clinical, Food Safety, Pharma QC and Water Quality
molecular testing. BioGX’s 60+ multiplex real-time PCR products are
marketed and sold in several countries through its Global
Distribution Network.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of BioGX and
its Xfree™ Assays or pixl™
instrument, Microbix and its QAPs, their relevance, or others’
products or services, business and business results, goals or
outlook, risks associated with financial results and stability,
development projects such as those referenced in its presentations,
regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity or timeliness of delivery),
currency exchange rates, maintaining adequate working capital or
raising new capital on acceptable terms or at all, and other
similar statements about anticipated future events, conditions or
results that are not historical facts. These statements reflect
management’s current estimates, beliefs, intentions, and
expectations; they are not guarantees of future performance.
Microbix cautions that all forward-looking information is
inherently uncertain and actual performance may be affected by many
material factors, some of which are beyond its control.
Accordingly, actual future events, conditions and results may
differ materially from the estimates, beliefs, intentions, and
expectations expressed or implied in the forward-looking
information. All statements are made as of the date of this news
release and represent Microbix’s judgement as of the date of this
new release, and it is under no obligation to update or alter any
forward-looking information.
Please visit https://microbix.com or
https://www.sedarplus.ca for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome,CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, PROCEEDx®, QAPs™, and REDx® are
trademarks of Microbix Biosystems Inc.Other companies’ names and
products are protected by their respective trademarks.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024